Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


1 Acta Radiol
2 Am J Clin Oncol
2 BJU Int
1 Br J Radiol
1 Eur Urol
1 Int J Cancer
1 Int J Urol
6 J Urol
2 PLoS One
4 Prostate
1 Radiology

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Acta Radiol

  1. DYRBERG E, Larsen EL, Hendel HW, Thomsen HS, et al
    Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
    Acta Radiol. 2018 Jan 1:284185117751280. doi: 10.1177/0284185117751280.
    PubMed     Text format     Abstract available

    Am J Clin Oncol

  2. TRAN S, Jorcano S, Falco T, Lamanna G, et al
    Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.
    Am J Clin Oncol. 2018 Jan 8. doi: 10.1097/COC.0000000000000419.
    PubMed     Text format     Abstract available

  3. KANG JJ, Reiter RE, Kummer N, DeKernion J, et al
    Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.
    Am J Clin Oncol. 2018;41:1-5.
    PubMed     Text format     Abstract available

    BJU Int

  4. LAZAREV S, Thompson MR, Stone NN, Stock RG, et al
    Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10 Years of Follow-Up.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14122.
    PubMed     Text format     Abstract available

  5. SCHLUSSEL MARKOVIC E, Buckstein M, Stone NN, Stock RG, et al
    Outcomes and Toxicities in Intermediate-Risk Prostate Cancer Patients Treated with Brachytherapy Alone or Brachytherapy and Supplemental External Beam Radiation Therapy.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14128.
    PubMed     Text format     Abstract available

    Br J Radiol

  6. ELFATAIRY KK, Filson CP, Sanda MG, Osunkoya AO, et al
    In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? a pilot test-retest reliability study.
    Br J Radiol. 2018 Jan 8:20170603. doi: 10.1259/bjr.20170603.
    PubMed     Text format     Abstract available

    Eur Urol

  7. UO T, Sprenger C
    Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward.
    Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31067.
    PubMed     Text format    

    Int J Cancer

  8. WU J, Wilson KM, Stampfer MJ, Willett WC, et al
    A 24-year prospective study of dietary alpha-linolenic acid and lethal prostate cancer.
    Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31247.
    PubMed     Text format     Abstract available

    Int J Urol

  9. MURATA Y, Tatsugami K, Yoshikawa M, Hamaguchi M, et al
    Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2018 Jan 8. doi: 10.1111/iju.13514.
    PubMed     Text format     Abstract available

    J Urol

  10. NGUYEN DP, Vertosick EA, Sharma V, Corradi RB, et al
    Does subclassification of pathologically organ-confined (pT2) prostate cancer provide prognostic discrimination of outcomes after radical prostatectomy?
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30005-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

    Re: Near-Infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer.
    J Urol. 2018;199:13-14.
    PubMed     Text format    

    Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2018;199:26-28.
    PubMed     Text format    

    Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
    J Urol. 2018;199:28.
    PubMed     Text format    

    Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    J Urol. 2018;199:7-8.
    PubMed     Text format    

    Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Urol. 2018;199:19-20.
    PubMed     Text format    

    PLoS One

  16. SRIVASTAVA P, Sarma A, Chaturvedi CM
    Targeting DNA repair with PNKP inhibition sensitizes radioresistant prostate cancer cells to high LET radiation.
    PLoS One. 2018;13:e0190516.
    PubMed     Text format     Abstract available

  17. BYUN SJ, Kim YS, Ahn H, Kim CS, et al
    Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients.
    PLoS One. 2018;13:e0190479.
    PubMed     Text format     Abstract available


  18. LIN HM, Lee BY, Castillo L, Spielman C, et al
    Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Prostate. 2018 Jan 5. doi: 10.1002/pros.23476.
    PubMed     Text format     Abstract available

  19. EKOUE DN, Ansong E, Liu L, Macias V, et al
    Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.
    Prostate. 2018 Jan 5. doi: 10.1002/pros.23471.
    PubMed     Text format     Abstract available

  20. ALBITAR M, Ma W, Lund L, Shahbaba B, et al
    Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.
    Prostate. 2018 Jan 8. doi: 10.1002/pros.23473.
    PubMed     Text format     Abstract available

  21. AZUMA T
    Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.
    Prostate. 2018 Jan 8. doi: 10.1002/pros.23470.
    PubMed     Text format    


  22. BOROFSKY S, George AK, Gaur S, Bernardo M, et al
    What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.
    Radiology. 2017 Oct 20:152877. doi: 10.1148/radiol.2017152877.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.